In his 2010 budget, President Barack Obama is proposing a more efficient process for approving generic biotech drugs, a move that won praise from generic-drug companies. The process would "mean huge savings for payers and insurance companies, patients, and state and local governments" and even federal programs, said Kathleen Jaeger, CEO of the Generic Pharmaceutical Association.

Related Summaries